We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+45.38%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$22.7B
AUM Growth
+$6.43B
Cap. Flow
-$298M
Cap. Flow %
-1.32%
Top 10 Hldgs %
85.22%
Holding
124
New
14
Increased
20
Reduced
17
Closed
10

Top Buys

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$116M
2
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$86.7M
3
ADCT icon
ADC Therapeutics
ADCT
+$64M
4
NVTA
Invitae Corporation
NVTA
+$48M
5
SYRE icon
Spyre Therapeutics
SYRE
+$20.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$416M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$101M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$51.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$36.8M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$23.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.74%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$8.03B 35.43%
47,269,424
-2,790,816
-6% -$416M
INCY icon
2
Incyte
INCY
$25.2B
$3.33B 14.67%
31,999,081
+20,296
+0.1% +$1.96M
ONC
3
BeOne Medicines Ltd
ONC
$34B
$2.22B 9.79%
11,777,285
– –
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$4.46B
$2.03B 8.96%
41,904,586
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$983M 4.34%
8,760,794
– –
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.9B
$936M 4.13%
7,589,294
– –
KOD icon
7
Kodiak Sciences
KOD
$2.44B
$626M 2.76%
11,574,538
– –
ASND icon
8
Ascendis Pharma A/S
ASND
$16.5B
$501M 2.21%
3,390,270
– –
NVTA
9
DELISTED
Invitae Corporation
NVTA
$359M 1.58%
11,850,962
+2,750,347
+30% +$48M
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$306M 1.35%
3,164,234
+1,390,000
+78% +$116M
AMRN
11
Amarin Corp
AMRN
$297M
$239M 1.05%
1,724,834
– –
ARGX icon
12
argenx
ARGX
$55.2B
$230M 1.01%
1,019,557
– –
IGMS
13
DELISTED
IGM Biosciences
IGMS
$230M 1.01%
3,144,223
+223
+0% +$13.5K
MDGL icon
14
Madrigal Pharmaceuticals
MDGL
$12.4B
$170M 0.75%
1,499,212
– –
MRTX
15
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$161M 0.71%
1,409,784
– –
EXAS
16
DELISTED
Exact Sciences
EXAS
$161M 0.71%
1,846,139
– –
NBIX icon
17
Neurocrine Biosciences
NBIX
$18.2B
$111M 0.49%
906,986
-333,257
-27% -$36.8M
PRNB
18
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$94.5M 0.42%
1,580,873
-374,540
-19% -$23.1M
FMTX
19
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$93M 0.41%
+2,000,000
New +$86.7M
CERS icon
20
Cerus
CERS
$577M
$90.5M 0.4%
13,713,195
– –
HRTX icon
21
Heron Therapeutics
HRTX
$92.4M
$88.5M 0.39%
6,018,104
– –
INSM icon
22
Insmed
INSM
$22.5B
$83.3M 0.37%
3,025,384
– –
AXSM icon
23
Axsome Therapeutics
AXSM
$11.7B
$83.1M 0.37%
1,009,757
+120,000
+13% +$9.24M
ADCT icon
24
ADC Therapeutics
ADCT
$139M
$79M 0.35%
+1,687,500
New +$64M
BCEL
25
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$75.2M 0.33%
3,532,760
– –
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2020 Portfolio in Review

As of Q2 2020, Baker Bros. Advisors held 124 positions worth $22.7B, up 40% from $16.2B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Baker Bros. Advisors's Q2 2020 filing shows 14 new, 20 increased, 17 reduced and 10 closed positions. Its largest new stake was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M. The largest sale was Seagen Inc. Common Stock, an estimated $416M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2020 buy was Forma Therapeutics Holdings, Inc. Common Stock: 2,000,000 shares worth $93M.
  • Baker Bros. Advisors added most to MyoKardia, Inc. Common Stock in Q2 2020, an estimated $116M increase.
  • Baker Bros. Advisors's biggest Q2 2020 reduction was Seagen Inc. Common Stock, cutting an estimated $416M.
  • Baker Bros. Advisors fully exited Ra Pharmaceuticals, Inc. Common Stock in Q2 2020, selling an estimated $101M.
  • Baker Bros. Advisors's ten largest holdings make up 85% of its $22.7B portfolio in Q2 2020.
  • Baker Bros. Advisors opened 14 new positions and closed 10 in Q2 2020.
  • Baker Bros. Advisors's portfolio value rose 40% quarter-over-quarter to $22.7B.

Based on Baker Bros. Advisors's 13F filing for Q2 2020, filed 14 Aug 2020.